東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

FindBook

Google Book

Amazon

博客來

Essays on Pharmaceuticals: Firm Competition, Usage, and Pricing.

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Essays on Pharmaceuticals: Firm Competition, Usage, and Pricing./
作者:	Cuddy, Emily Ann.
出版者:	Ann Arbor : ProQuest Dissertations & Theses, : 2021,
面頁冊數:	168 p.
附註:	Source: Dissertations Abstracts International, Volume: 83-04, Section: B.
Contained By:	Dissertations Abstracts International83-04B.
標題:	Pharmaceutical sciences. -
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=28643288
ISBN:	9798460486137

Essays on Pharmaceuticals: Firm Competition, Usage, and Pricing.
Cuddy, Emily Ann.

Essays on Pharmaceuticals: Firm Competition, Usage, and Pricing. - Ann Arbor : ProQuest Dissertations & Theses, 2021 - 168 p.

Source: Dissertations Abstracts International, Volume: 83-04, Section: B.

Thesis (Ph.D.)--Princeton University, 2021.

This item must not be sold to any third party vendors.

Pharmaceuticals play a crucial role in the US health care system. My dissertation consists of three chapters that examine the economics of pharmaceutical markets. In particular, I examine how firm competition, physician prescribing decisions, and price dispersion affect US consumers. In Chapter 1, I examine the role of competition in the US generic drug market in the wake of the unprecedented price spikes of the past decade, which have been linked to the collusive conduct of manufacturers. Using unsealed records of the ring's activity, I analyze how collusion-in combination with other contemporaneous features of the market-affected upstream drug prices by estimating a model of retail drug procurement, wherein generic manufacturers submit bids to supply national pharmacies with their drugs. Estimates suggest that the collusive ring generated billions in surplus for itself over 18 months and, moreover, that the unprecedented backlog of generic drug applications at the Food and Drug Administration in this period exacerbated the situation. In Chapter 2, Janet Currie and I study how initial mental health treatment affects the outcomes of adolescents. Using a large national data base of insurance claims, we find evidence that receiving follow-up mental health treatment in the first three months after an initial episode increases health care costs over the next 24 months. Moreover, these higher costs are entirely accounted for by children who receive treatment that is not consistent with practice guidelines, and especially by those who receive drugs that raise a red-flag. Finally, in Chapter 3, I examine price dispersion in the US over-the-counter drug market. Analysis of weekly sales data over the last decade for over 4,000 drug products suggests that there is widespread price dispersion across the country, even at the granularity of the universal product code. Consistent with recent discussions of health care exceptionalism, I find evidence that much of the dispersion can be explained by preexisting theories of price dispersion, including costly consumer search, store-level amenities, and retail-chain effects.

ISBN: 9798460486137Subjects--Topical Terms:

3173021
Pharmaceutical sciences.
Subjects--Index Terms:

Pharmaceuticals

Essays on Pharmaceuticals: Firm Competition, Usage, and Pricing.
LDR:03223nmm a2200349 4500 001 2349318
005 20220920133718.5
008 241004s2021 ||||||||||||||||| ||eng d
020 $a 9798460486137
035 $a (MiAaPQ)AAI28643288
035 $a AAI28643288
040 $a MiAaPQ $c MiAaPQ
100 1 $a Cuddy, Emily Ann. $3 3688728
245 1 0 $a Essays on Pharmaceuticals: Firm Competition, Usage, and Pricing.
260 1 $a Ann Arbor : $b ProQuest Dissertations & Theses, $c 2021
300 $a 168 p.
500 $a Source: Dissertations Abstracts International, Volume: 83-04, Section: B.
500 $a Advisor: Currie, Janet;Ho, Kate.
502 $a Thesis (Ph.D.)--Princeton University, 2021.
506 $a This item must not be sold to any third party vendors.
520 $a Pharmaceuticals play a crucial role in the US health care system. My dissertation consists of three chapters that examine the economics of pharmaceutical markets. In particular, I examine how firm competition, physician prescribing decisions, and price dispersion affect US consumers. In Chapter 1, I examine the role of competition in the US generic drug market in the wake of the unprecedented price spikes of the past decade, which have been linked to the collusive conduct of manufacturers. Using unsealed records of the ring's activity, I analyze how collusion-in combination with other contemporaneous features of the market-affected upstream drug prices by estimating a model of retail drug procurement, wherein generic manufacturers submit bids to supply national pharmacies with their drugs. Estimates suggest that the collusive ring generated billions in surplus for itself over 18 months and, moreover, that the unprecedented backlog of generic drug applications at the Food and Drug Administration in this period exacerbated the situation. In Chapter 2, Janet Currie and I study how initial mental health treatment affects the outcomes of adolescents. Using a large national data base of insurance claims, we find evidence that receiving follow-up mental health treatment in the first three months after an initial episode increases health care costs over the next 24 months. Moreover, these higher costs are entirely accounted for by children who receive treatment that is not consistent with practice guidelines, and especially by those who receive drugs that raise a red-flag. Finally, in Chapter 3, I examine price dispersion in the US over-the-counter drug market. Analysis of weekly sales data over the last decade for over 4,000 drug products suggests that there is widespread price dispersion across the country, even at the granularity of the universal product code. Consistent with recent discussions of health care exceptionalism, I find evidence that much of the dispersion can be explained by preexisting theories of price dispersion, including costly consumer search, store-level amenities, and retail-chain effects.
590 $a School code: 0181.
650 4 $a Pharmaceutical sciences. $3 3173021
653 $a Pharmaceuticals
653 $a Firm competition
653 $a Usage
653 $a Pricing
690 $a 0501
690 $a 0572
710 2 $a Princeton University. $b Economics. $3 2093738
773 0 $t Dissertations Abstracts International $g 83-04B.
790 $a 0181
791 $a Ph.D.
792 $a 2021
793 $a English
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=28643288